Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline.

about

Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline.

Item

http://www.wikidata.org/entity/Q47096976

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline.

@en

Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline.

@nl

type

Item

label

Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline.

@en

Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline.

@nl

prefLabel

Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline.

@en

Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline.

@nl

P1476

Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline.

@en

P2093

Gynecologic Cancer Disease Site Group

http://www.w3.org/2001/XMLSchema#string

H Mackay

http://www.w3.org/2001/XMLSchema#string

J Francis

http://www.w3.org/2001/XMLSchema#string

L Elit

http://www.w3.org/2001/XMLSchema#string

N Coakley

http://www.w3.org/2001/XMLSchema#string

P2860

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.

Cancer of the ovary.

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

P304

e540-e546

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.24.3824

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29270064

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

5736494

http://www.w3.org/2001/XMLSchema#string